Giuseppe Curigliano
A5003897511- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- BRCA gene mutations in cancer
- Economic and Financial Impacts of Cancer
- Radiopharmaceutical Chemistry and Applications
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- Global Cancer Incidence and Screening
- Estrogen and related hormone effects
- Biosimilars and Bioanalytical Methods
- PARP inhibition in cancer therapy
- Chemotherapy-induced cardiotoxicity and mitigation
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Lymphocytic Leukemia Research
European Institute of Oncology
2016-2025
University of Milan
2014-2025
Ripamonti
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2025
Istituto Oncologico Veneto
2014-2025
Memorial Sloan Kettering Cancer Center
2016-2024
Ludwig-Maximilians-Universität München
2024
Harbin Medical University
2024
National Hospital Organization Kyushu Cancer Center
2024
Institut Jules Bordet
2016-2024
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Background— Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification lacking. We prospectively evaluated incidence, time occurrence, clinical correlates, response to heart failure therapy cardiotoxicity. Methods Results— assessed left ventricular ejection fraction (LVEF), at baseline, every 3 months during chemotherapy for the following year, 6 over 4 years, yearly...
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy multiple HER2-targeted agents limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. We randomly assigned patients HER2-positive previously treated trastuzumab, pertuzumab, and trastuzumab emtansine, had or did not brain metastases, to receive either tucatinib placebo, in combination...
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after a combination of anti-HER2 antibodies and taxane.We conducted phase 3, multicenter, open-label, randomized trial to compare efficacy safety trastuzumab deruxtecan (a HER2 antibody-drug conjugate) those in HER2-positive previously treated taxane. The primary end point was progression-free survival (as...
The Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24-25 June 2014. meeting a true translational where researchers clinicians shared their results, experiences, insights order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, optimal dosage are still not well understood the field would learn lot from ancillary studies performed during clinical trials chemotherapies. From...
Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line treatment patients with mTNBC.
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer.
In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) tucatinib. We describe exploratory analyses of intracranial efficacy and participants BMs.Patients were randomly assigned 2:1 to tucatinib or placebo, combination trastuzumab capecitabine. All underwent baseline magnetic resonance imaging; those BMs classified as active stable....